Study sets benchmark for cost of repurposed coronavirus drug...

Scientists have warned that the main drugs being repurposed for COVID-19 could end up being too expensive for many people around the world – unless drugmakers are prepared to s

Surviving as a rare disease biotech during COVID-19

With trial delays, social distancing, and falls in charitable funding, the coronavirus pandemic presents some serious challenges for nonprofit orphan disease biotechs like Cure Rare Disease

Japan approves Gilead's COVID-19 drug remdesivir

Japan’s regulator has quickly approved Gilead’s remdesivir for patients with severe COVID-19, after the FDA allowed its use as an emergency treatment for the disease earlier this month.

Coping with a life-changing diagnosis during COVID-19

As the UK went into COVID-induced lockdown, Matthew and Hayley Smith were receiving the news they had dreaded for four years – that Matthew’s brain tumour had come back.

Doubts over US government plans for COVID-19 vaccine

There are doubts about the US government's plans to have 300 million COVID-19 vaccine doses ready by the end of the year, after the front-running candidate from Moderna advanced to mid-stag

AI tool spots 59 possible COVID-19 drugs in UK Biobank data